Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of SLC-391 in Healthy Subjects
NCT05278845Phase 1Completed
- Sponsor
- SignalChem Lifesciences Corporation
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of slc-391 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by SignalChem Lifesciences Corporation. Primary endpoints: Area Under the Plasma Concentration versus Time Curve at 14 days and Maximum Observed Plasma Concentration at 14 days. Started Feb 2022; status: completed.
02
Drugs
slc-391
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05278845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278845.